Another aspect that has not been discussed much on here is cost.
If we assume efficacy and safety parameters are (or will be) ticked then the remaining questions relating to QA and manufacturing are (one would think) attainable but potential delays. My point is that they are attainable - process driven it looks likely.
As such:
1. Delays potentially: Loss of life.
2. Increased cost: Costs would of been discussed prior to today and QA and manufacturing costs will increases through this line of questioning. The solution becomes higher in costs making it less attainable.
The FDA will know that by 'fort knoxing' Mesoblast it takes it further away from the people that need it (as I said if they agree with the sentiment of efficacy and safety above). It's a balancing act with children's lives on one side of the ledger. Tough job!
- Forums
- ASX - By Stock
- MSB
- FDA ODAC Meeting Material discussion analysis
FDA ODAC Meeting Material discussion analysis, page-337
-
- There are more pages in this discussion • 155 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 75212 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 1.185 |
1 | 20000 | 1.175 |
1 | 5664 | 1.170 |
1 | 17568 | 1.160 |
3 | 56695 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 59712 | 2 |
1.195 | 36255 | 5 |
1.200 | 404381 | 31 |
1.205 | 3000 | 1 |
1.210 | 162475 | 7 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |